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Small colony variants (SCVs) of bacteria like Staphylococcus aureus are characterized
by a reduced colony size and are linked to increased antibiotic tolerance and
resistance. Their altered expression of virulence factors, slow growing properties and
their ability to form biofilms make the eradication of SCVs challenging. In the context of
biofilm-related infectious diseases involving S. aureus SCVs, a therapy targeting bacterial
iron metabolism was evaluated. The combination of the iron-chelator deferiprone (Def)
and the heme-analog gallium-protoporphyrin (GaPP), in solution and incorporated in
a surgical wound gel, was tested for activity against planktonic and sessile SCVs. To
this end, the activity of Def-GaPP was assessed against planktonic S. aureus SCVs,
as well as against in vitro and in vivo biofilms in the colony biofilm model, an artificial
wound model and a Caenorhabditis elegans infection model. While Def alone failed
to show substantial antibacterial activity, GaPP and the combination of Def-GaPP
demonstrated concentration- and strain-dependent antibacterial properties. Specifically,
the Def-GaPP combination significantly reduced the bacterial load in an artificial wound
model and increased the survival of S. aureus SCV infected C. elegans. When Def-GaPP
were combined with gentamicin or ciprofloxacin, the triple combinations exceeded the
antibiofilm activity of the individual compounds in the colony biofilm model. In targeting
bacterial iron metabolism, Def-GaPP showed significant activity against planktonic and
sessile SCVs. Moreover, Def-GaPP could potentiate the activity of gentamicin and
ciprofloxacin. Delivered in a wound healing gel, Def-GaPP showed promise as a new
topical strategy against infections with S. aureus SCVs.
Keywords: biofilms, small colony variants, Staphylococcus aureus, iron, deferiprone, gallium-protoporphyrin,
wound models, Caenorhabditis elegans
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INTRODUCTION
Small colony variants (SCVs) are naturally occurring bacteria
derived from a parent strain characterized by a small colony
morphology (∼10% the size of the parent strain colony), slow
growth rate, altered virulence factors and increased antibiotic
tolerance or resistance (Proctor et al., 2006). The switch to a
phenotypic altered strain can be inheritable or transient (Johns
et al., 2015). Staphylococcus aureus SCVs are frequently non-
pigmented, non-hemolytic, and dependent on external growth
factors like menadione, hemin, and thymidine; they are able to
survive inside eukaryotic cells, including human macrophages
(von Eiff et al., 1997b; Proctor et al., 2006; Garcia L. et al.,
2012). Due to their intracellular lifestyle, S. aureus SCVs can
escape the immune attack and are protected against antibiotics
leading to persistence of disease. SCVs are associated with
antibiotic-refractory and recalcitrant infections, such as chronic
rhinosinusitis, respiratory tract infections in cystic fibrosis,
osteomyelitis, chronic wounds, or implant infections (Proctor
et al., 2006; Garcia et al., 2013; Tan et al., 2014). The recovery of
SCVs in routine clinical investigations requires special nutrients
and prolonged culture, making SCV isolation and identification
difficult (von Eiff, 2008). Prolonged treatment regimens with
a variety of antibiotics are required to treat SCV-associated
infections, often combined with surgical interventions. However,
clinical outcomes are frequently unsatisfying due to treatment
failure and recurrence of disease (Garcia et al., 2013).
Worsening the situation, SCVs can be induced by medical
therapies e.g., by exposure to antibiotics such as gentamicin, or
disinfectants such as triclosan (von Eiff et al., 1997a; Bayston
et al., 2007). It is furthermore known that sub-therapeutic
antibiotic exposure can trigger biofilm formation of S. aureus
SCVs and their parent strains, further complicating treatment
(Costerton et al., 1995; Mitchell et al., 2010a,b). Despite the
clinical significance there is little knowledge concerning S. aureus
SCV biofilms and their susceptibility to antibiotics. Innovative
treatment approaches, based on compounds with a different
mode of action, such as disrupting bacterial iron metabolism
(Richter et al., 2017a), may be a strategy worth approaching. S.
aureus SCVs, like all bacteria, rely on iron for growth and survival
(Andrews et al., 2003), hence, the iron metabolism could be an
interesting therapeutic target.
In the present study, the antimicrobial activity of a treatment
combining the iron-chelator deferiprone (Def) and the heme
analog gallium-protoporphyrin (GaPP) was assessed against
planktonic and biofilm-associated SCVs.
MATERIALS AND METHODS
Bacterial Strains
Bacterial strains were collected from the sinonasal cavities of
chronic rhinosinusitis patients. Ethics approval was obtained
from The Queen Elizabeth Hospital Human Research Ethics
Committee, Woodville, SA, Australia. Strains included one S.
aureus clinical isolate (parent strain P1), which was prolonged
subcultured at MIC or higher concentrations of gentamicin (≥2
µg/ml). This induced small colony variants (SCV1) that featured
elevated gentamicin tolerance. Another strain was a clinically
isolated S. aureus small colony variant (SCV2).
Characteristics of Bacterial Strains
Catalase, Coagulase, and Hemolytic Activity
Catalase and coagulase activity of bacterial strains were
determined by suspending cells in saline in a glass tube.
The catalase activity was observed by gas formation following
addition of hydrogen peroxide. The coagulase activity was
determined by clumping of bacterial cells after addition of
plasma. Hemolytic activity was determined by streaking out
bacteria on sheep blood agar (Oxoid, Thermo Fisher Scientific,
Scoresby, VIC, Australia). Following incubation at 37◦C for 24 h
the presence of a hemolysis zone was observed.
Auxotrophy Determination
The auxotrophy type of bacteria was determined as previously
described (van de Rijn and Kessler, 1980). Briefly, a bacterial
suspension adjusted to 1.0 McFarland units (∼3 × 108
CFU/ml) was diluted 1:100 in physiological saline. One hundred
microliters were spread on chemically defined medium agar (van
de Rijn and Kessler, 1980). Sterile disks were infiltrated with
10 µl of hemin, menadione, and thymidine, respectively, and
placed on top of the agar. Plates were incubated for 48 h at 37◦C.
According to the growth zones around the disks auxotrophy was
determined.
MIC Determination
The colony suspension and broth microdilution method
(Wiegand et al., 2008) were used to determine the MIC of
deferiprone (Def, 3-hydroxy-1,2-dimethylpyridin-4(1H)-one,
Sigma, Castle Hill, NSW, Australia) and gallium-protoporphyrin
IX (GaPP, Frontier Scientific, Logan, UT) over 48 h. The
concentrations ranged from 0.08 to 40 mM Def (i.e., 10.8–
5,568 µg/ml) and 0.1–50 µg/ml GaPP. In addition, the
MICs of ciprofloxacin (Cip), gentamicin (Gent), mupirocin
(Mup), doxycycline (Doxy), chloramphenicol (Chlor),
cephalexin (Ceph), vancomycin (Van), amoxicillin (Amoxi),
and streptomycin (Strep) were determined (concentration range
0.06–32 µg/ml). All compounds were purchased from Sigma
unless stated differently.
Bacterial Growth
Bacteria were suspended in tryptone soya broth (Oxoid) and
adjusted to an OD 600 of 0.01. Bacterial growth was measured
in a 96-well plate over 40 h at 37◦C using an EnSpire Multimode
Plate Reader (Perkin Elmer, Waltham, MA). Loops were taken
after 24 and 40 h to determine the colony morphology.
Hydrogel Preparation
Hydrogels were prepared by adequate mixing of dextran-
aldehyde, succinyl-chitosan, and a buffer solution, as previously
described (Richter et al., 2017b). Def (20 mM) and/or GaPP
(100 or 500 µg/ml) were incorporated in the gel and compared
to blank gel and antibiotic loaded gel including 5 µg/ml
ciprofloxacin (Cip) and 100 µg/ml gentamicin (Gent). Cip and
Gent were chosen due to their clinical relevance as antibiotic
therapies for respiratory tract, skin, blood, bone, and soft tissue
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infections. Furthermore, fluoroquinolone antibiotics (such as
Cip) were described as being highly effective against SCVs in vitro
and in vivo (Garcia L. et al., 2012; Garcia et al., 2013).
In vitro Activity in the Colony Biofilm Model
A bacterial suspension was prepared in 0.9% saline and adjusted
to 1.0 McFarland units (∼3 × 108 CFU/ml). After diluting
bacteria 1:1,000 in tryptone soya broth, 2 µl were spotted
on UV-sterilized Whatman polycarbonate membrane filters
(0.2 µm pore size, GE Healthcare, Little Chalfont, UK) and
placed on tryptone soya agar (Merritt et al., 2005). Following
biofilm formation after 24 h incubation at 37◦C, the membrane
filters were transferred onto AB trace agar (minimal growth
agar including 0.5% glucose and 0.5% peptone). One hundred
microliters of freshly prepared hydrogel was placed on biofilms
and incubated for 2.5 days at 37◦C. The filter membranes were
then aseptically transferred to new AB trace agar plates and
incubated for 2.5 days at 37◦C. Finally, the filters were collected
in PBS to extract bacteria by vortexing (1 min) and sonication (15
min), prior to serial dilutions and plating on tryptone soya agar
for CFU counting and colony morphology determination after 3
days incubation at 37◦C.
The antibiofilm effect of drug loaded gels was rated
using the Bliss Independence Model (Morones-Ramirez et al.,
2013; Thangamani et al., 2015). The synergy of treatment
combinations (Def-GaPP100, Def-GaPP100-Cip, Def-GaPP100-
Gent, Def-GaPP500) was calculated according to the following
equation, with values above zero corresponding to synergistic
effects.
S =
( a
MG
)
∗
(
b
MG
)
−
(
ab
MG
)
(1)
S = synergistic effect, a = Log10 of biofilm after exposure to
compound a, b = Log10 of biofilm after exposure to compound
b, ab= Log10 of biofilm after exposure to treatment combination
ab,MG= Log10 of untreated biofilm (maximum growth).
In vitro Activity in an Artificial Wound
Model
Hyaluronic acid (1.20–1.80 MDa, Lifecore Biomedical, Chaska,
MN) and collagen (Corning Incorporated, Corning, NY) were
used to prepare an artificial dermis (Brackman et al., 2016), which
was immersed in lyophilized bovine plasma, 19 ml Bolton broth
(Oxoid), 1ml horse blood and 10 IU of heparin. Subsequently,
10µl of an overnight culture adjusted to 1 × 106 CFU/ml was
spotted on top of the dermis and incubated for 24 h at 37◦C. The
formed biofilms were exposed to 150µl gel (blank gel, Def, GaPP
500, Def-GaPP500, and Cip gels) for 24 h at 37◦C. Following a
washing step, the dermis was immersed in 10 ml of 0.9% saline
to recover the bacteria by vortexing and sonication (alternating
cycles of 3 × 30 s), prior to serial dilutions and plating for CFU
counting. In addition, the colony morphology was determined.
In vivo Activity in a C. elegans Infection
Model
Synchronized nematodes, Caenorhabditis elegans AU37 (glp-4;
sek-1), were grown to L4 stage, suspended in OGM medium
(95% M9 buffer, 5% brain heart infusion broth, 10 µg/ml
cholesterol) and added into 96-well plates with at least 20 worms
per well (Brackman et al., 2011). Nematodes were infected with
25 µl of an overnight culture adjusted to 2 × 109 CFU/ml
in OGM medium and exposed to 25 µl of treatment (Def 20
mM, GaPP 500 µg/ml or a combination of both). Uninfected
nematodes in OGM medium as well as infected but untreated
nematodes were used as controls. The number of viable and dead
nematodes was assessed every 24 h over 3 days incubation at
25◦C. Subsequently, nematodes were first washed in M9 buffer
containing 1 mM sodium azide, then washed in PBS prior
to counting. The nematodes were mechanically disrupted by
vortexing the worms in microtubes with 1.0 mm silicon carbide
beads for 10 min (BioSpec Products, Bartlesville, OK). Serial
dilutions of the supernatants were plated (tryptone soya agar
with 7.5% NaCl) for CFU counting and colony morphology
determination.
Statistics and Software
All experiments were conducted in triplicate and are presented
as mean ± standard deviation (SD) or mean ± standard error of
the mean (SEM). Results were analyzed using two-way analysis
of variance with Dunnett’s test (GraphPad Prism version 7.02,
GraphPad Software, La Jolla, CAL). Statistical significance was
assessed at the 95% confidence level.
FIGURE 1 | S. aureus small colony variant SCV1 (A), SCV2 (B), and parent
strain P1 (C).
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FIGURE 2 | Growth curves of small colony variant SCV1 (green triangles),
SCV2 (red dots) and parent strain P1 (blue diamonds).
TABLE 1 | Characteristics of small colony variant SCV1, SCV2, and parent strain
P1, including catalase, coagulase and hemolytic activity, auxotrophy type, as well
as MICs (in µg/ml) of deferiprone (Def), gallium-protoporphyrin (GaPP), the
combination of both compounds, ciprofloxacin (Cip), gentamicin (Gent), mupirocin
(Mup), doxycycline (Doxy), chloramphenicol (Chlor), cephalexin (Ceph),
vancomycin (Van), amoxicillin (Amoxi), and streptomycin (Strep).
SCV 1 SCV 2 P1
Catalase Positive Negative Positive
Coagulase Positive Positive Negative
Hemolysis Positive Negative Positive
Auxotrophy Hemin/menadione Thymidine Hemin/menadione
Def 1,392 348 5,568
GaPP 6.25 >50 12.5
Def-GaPP 348/3.125 174/1.56 1,392/12.5
Cip 2 4 0.5
Gent 16 16 2
Mup 0.25 >32 1
Doxy 4 0.5 0.25
Chlor 8 4 8
Ceph 2 >32 4
Van 1 >32 2
Amoxi 32 >32 4
Strep >32 >32 32
RESULTS
Characteristics of Bacterial Strains
The colony morphology of bacterial strains is shown in Figure 1
and the growth curves are displayed in Figure 2. A summary of
bacterial characteristics is shown in Table 1.
SCV1 was observed to be a catalase positive, coagulase
positive, and hemolysis positive strain with hemin/menadione
auxotrophy. SCV2 was determined as a catalase negative,
coagulase positive, and hemolysis negative strain with thymidine
auxotrophy. P1 was identified to be catalase positive, coagulase
negative, and hemolysis positive with hemin/menadione
auxotrophy. As depicted in Figure 2, during 24 h SCV1 and
SCV2 showed a slower growth rate and a lower OD 600 value
than the parent strain P1. While SCV1 reached stationary and
decline phase after 24 h, SCV2 continued to grow reaching an
OD 600 of 0.95 after 40 h. Loops taken after 24 h revealed a small
colony morphology for both SCV1 and SCV2, while after 40 h
SCV2 presented as a mix of small colonies and very few normal
sized colonies. SCV1 showed a small morphology after 40 h.
SCV1 and SCV2 were 4- and 16-fold more susceptible to Def
and 4- and 8-fold less susceptible to Cip and Gent compared
to the parent strain P1. SCV1 and P1 had low MICs for GaPP
(6.25 and 12.5 µg/ml, respectively), while SCV2 was observed
to have a MIC above 50 µg/ml for GaPP. The MICs for the
Def-GaPP combination were typically lower than the MICs for
individual compounds, however, the extent of this difference was
strain-dependent. As displayed in Table 1, SCV1 was susceptible
to Mup and Van, and showed increasing MIC values for Ceph,
Doxy, and Chlor, and was not susceptible to Amoxi and Strep.
SCV2 was susceptible to Doxy, less susceptible to Chlor and
not susceptible to Mup, Ceph, Van, Amoxi, and Strep. P1
showed lowMIC values for Doxy andMup, and increasing MICs
for Van, Ceph, Amoxi, and Chlor, and was not susceptible to
Strep.
Colony Biofilm Model
The blank gel and the Def gel showed no antibiofilm activity (data
not shown), while the GaPP gel demonstrated a concentration-
and strain-dependent effect. Gel loaded with a low concentration
of GaPP (100 µg/ml) showed a log10 reduction of 1.7 and 1.8
against biofilms of SCV1 and its parent strain P1, respectively,
but no antibiofilm activity against SCV2 (data not shown),
while at 500µg/ml GaPP showed a log10 reduction of 4.3,
1.4, and 2.0 in SCV1, SCV2, and P1 biofilms (Figure 3). Cip
and Gent loaded gels were observed to have only a minor
effect against SCV1, SCV2, and P1 (log10 reduction of 0.4, 0.1,
and 1.1, respectively for Cip and 0.2, 0.8, and 1.1, respectively
for Gent). A small colony morphology of both SCV1 and
SCV2 has been observed when analyzing CFUs after treatment
exposure.
The hemin auxotroph SCV1 (Figure 3A) showed increased
susceptibility to gel loaded with Def-GaPP100-Cip, Def-
GaPP100-Gent, GaPP 500, and Def-GaPP500 (log10 reduction of
3.4, 5.4, 4.3, and 4.4, respectively), and decreased susceptibility
to monotherapy with Cip or Gent compared to its parent strain
P1. Interestingly, Def-GaPP100 combined with Gent showed a
high degree of synergy (Figure 4) and significant activity against
the highly Gent-tolerant SCV1 compared to Gent alone and Def-
GaPP100 (log10 reduction of 5.4 for Def-GaPP100-Gent vs. 0.2
for Gent and 1.3 for Def-GaPP100, p < 0.0001).
The thymidine auxotroph SCV2 (Figure 3B) showed elevated
susceptibility to gel incorporating Def-GaPP100-Cip, Def-
GaPP100-Gent, GaPP 500, and Def-GaPP500 (log10 reduction
of 3.1, 1.7, 1.4, and 2.5, respectively), and no susceptibility to
Cip or Def-GaPP100. Notably, Def-GaPP100 combined with
Cip showed high synergy (Figure 4) and significant activity
against SCV2, manifestly exceeding the effect of the individual
compounds and Def-GaPP100 (log10 reduction of 3.1 for Def-
GaPP100-Cip vs. 0.1 for Cip and 0.1 for Def-GaPP100, p <
0.0001).
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FIGURE 3 | Log10 reduction of small colony variant SCV1 (A), SCV2 (B) and
parent strain P1 (C) colony biofilms after exposure to drug loaded hydrogels
compared to untreated control. 1: Gentamicin (Gent) 100 µg/ml (light gray), 2:
Ciprofloxacin (Cip) 5 µg/ml (purple), 3: Deferiprone (Def, 20
mM)-Gallium-protoporphyrin (GaPP) 100 µg/ml (blue), 4: Def-GaPP100-Cip
(black), 5: Def-GaPP500 (red), 6: GaPP 500 (orange), 7: Def-GaPP100-Gent
(dark gray). Data represent the mean ± SD of three biological replicates. Op <
0.001; #p < 0.0001; ns-not statistically significant.
Against the hemin auxotroph P1 (Figure 3C) the combination
of Def-GaPP100 gel with Cip or Gent showed significantly higher
activity than the antibiotics alone (log10 reduction of 1.8 for
Def-GaPP100-Cip vs. 1.1 for Cip, p < 0.001; and 1.9 for Def-
GaPP100-Gent vs. 1.1 for Gent, p < 0.0001). However, no
synergistic effect was observed compared to the Def-GaPP100 gel
(1.8 log10 reduction). The highest activity against P1 was achieved
with Def-GaPP500 gel (2.4 log10 reduction).
Macroscopic Biofilm Analysis
The antibiofilm activity of loaded hydrogels was macroscopically
analyzed over 5 days of treatment exposure. All biofilms grew
extensively when exposed to blank gel and gel incorporating Def
(not shown), Cip and Gent (Figure 5). A concentration- and
strain-dependent antibiofilm effect was apparent after exposure
FIGURE 4 | Synergy of treatment combinations against small colony variant
SCV1, SCV2 and parent strain P1 colony biofilms. Deferiprone 20 mM
(Def)-Gallium-protoporphyrin (GaPP) 100 µg/ml (blue circles), Def-GaPP500
µg/ml (red squares), Def-GaPP100-ciprofloxacin 5 µg/ml (black triangles),
Def-GaPP100-gentamicin 100 µg/ml (gray diamonds). The higher the value
the higher the degree of synergy.
to gels incorporating GaPP (not shown), Def-GaPP, Def-GaPP-
Cip, and Def-GaPP-Gent. While Def-GaPP100 gel moderately
inhibited bacterial growth, the combination of Def-GaPP100
with either Cip or Gent resulted in a substantial antibiofilm effect
(Figure 5).
Artificial Wound Model
Biofilms grown on an artificial dermis were exposed to drug
loaded hydrogels to determine the antibiofilm activity in an in
vitro wound model (Figure 6). The visual analysis of CFUs after
treatment exposure confirmed a small colonymorphology for the
majority of both SCV1 and SCV2. The untreated control and
the blank gel showed similar growth of all biofilms, indicating
no antibiofilm effect of the blank gel. The Def gel demonstrated
substantial antibiofilm activity against SCV1 (log10 reduction
of 0.9), but failed to be effective against P1 and SCV2. The
GaPP 500 gel showed minor antibiofilm activity with a 0.2–0.4
log10 reduction. In contrast, Def-GaPP500 gel showed significant
antibiofilm effects against SCV1, SCV2, and P1 with a 1.4, 1.0,
and 0.9 log10 reduction, respectively, thereby demonstrating
significantly higher activity than the individual compounds (p <
0.05–0.0001) and slightly higher activity than Cip gel (Figure 6).
In vivo Infection Model in C. elegans
Nematodes were infected with bacteria and their survival rate was
determined with and without Def, GaPP 500, or Def-GaPP500
treatment (Figure 7). The worm killing was strain-dependent
with 75, 25, and 57% survival in SCV1, SCV2, and P1 infected
worms, respectively, while uninfected controls showed 88%
survival over 3 days. When worms were exposed to Def, 45, 73,
and 71% of SCV1, SCV2, and P1-infected nematodes survived,
while 73, 48, and 81% infected worms survived when treated
with GaPP 500. The combination of Def-GaPP500 showed a
similar survival rate in SCV1 and P1 infected worms as GaPP
500 alone (71 and 87% survival, respectively). In contrast, the
survival rate of SCV2 infected worms was substantially higher
(86% survival) when treated with Def-GaPP500 compared to the
individual treatments. Compared to the uninfected control the
Def-GaPP500 treatment achieved similar survival rates in SCV2
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FIGURE 5 | Inhibitory effect of drug loaded hydrogels on biofilms after 5 days exposure. Elevated biofilm inhibition was observed for gels containing deferiprone,
gallium-protoporphyrin and ciprofloxacin or gentamicin (DGCip, DGGent). Strains used: Small colony variant SCV1, SCV2 and parent strain P1. Hydrogels- B, Blank
control gel; Cip, Ciprofloxacin 5µg/ml; Gent, Gentamicin 100µg/ml; DG, Deferiprone 20 mM-Gallium-protoporphyrin 100µg/ml; DGGent, Def-GaPP100-Gent;
DGCip, Def-GaPP100-Cip.
and P1 infected worms. Furthermore, the survival of SCV1 and
P1 infected worms after GaPP 500 treatment was not different to
uninfected controls (Figure 7).
Following 3 days of infection the bacterial load per worm
was quantified (Figure 8) by enumeration of CFU. Small colony
phenotypes of SCV1 and SCV2 were observed. Consistent with
results in the colony biofilm model and wound model, the
treatment with Def alone showed no significant effect and failed
to reduce the CFU per worm. In contrast, both GaPP 500 and
Def-GaPP500 showed a significant (p < 0.05) reduction of the
bacterial load, resulting in a log10 of 2.0 for GaPP and 2.3 for
Def-GaPP in SCV1 infected worms (SCV1 infection control:
log10 of 3.6 CFU/worm), 2.9 and 2.5 in P1 infected worms
(P1 infection control: log10 of 3.6 CFU/worm), and 3.0 and 2.8
in SCV2 infected worms (SCV2 infection control: log10 of 4.5
CFU/worm).
DISCUSSION
S. aureus SCVs in planktonic and biofilm form have a global
significance in the clinical environment being associated with
treatment failure and recurrence of disease (Proctor et al., 2006;
Garcia et al., 2013). Treatments are mostly based on antibiotics,
however, the low growth rate, reduced antibiotic susceptibility
and emerging resistance of SCVs pose a challenge for efficient
medical therapies. In the present study, an alternative treatment
that relies on the disruption of bacterial iron metabolism was
evaluated. As previously described, the iron chelator Def and
the heme analog GaPP show synergistic effects against S. aureus
biofilms in vitro (Richter et al., 2016). Herein, the activity of
Def-GaPP against planktonic and biofilm-associated SCVs and
FIGURE 6 | Effects of hydrogels in an artificial wound model compared to
untreated control. Log10 reduction of small colony variant SCV1, SCV2, and
parent strain P1 after exposure to hydrogels loaded with ciprofloxacin 5 µg/ml
(purple), deferiprone 20 mM (Def, gray), gallium-protoporphyrin 500 µg/ml
(GaPP, orange), and Def-GaPP500 (red). Data represent the mean ± SD of
three biological replicates. *p < 0.05; **p < 0.01; #p < 0.0001.
a parent strain with elevated antibiotic tolerance/resistance was
evaluated in vitro and in vivo.
The Def-GaPP treatment exhibits antimicrobial activity
based on the initial iron-chelation by Def, followed by iron
depletion-induced upregulation of the bacteria’s iron acquisition
systems (Haley and Skaar, 2012). The latter are exploited
by the heme analog GaPP mimicking heme as the preferred
iron source of S. aureus (Stojiljkovic et al., 1999; Skaar
et al., 2004; Weinberg, 2009). Inside bacteria, GaPP disrupts
the iron metabolism vital for bacterial growth, survival, and
virulence (Weinberg, 2009; Skaar, 2010). Unlike heme, GaPP
lacks the ability to transfer electrons, hence, GaPP cannot
be part of redox reactions required for respiration, ATP
production and DNA synthesis. Furthermore, GaPP cannot
be cleaved by bacterial enzymes and cannot be utilized as
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 6 June 2017 | Volume 7 | Article 280
Richter et al. Deferiprone and Gallium-Protoporphyrin Kill SCVs
FIGURE 7 | C. elegans survival (%) over 3 days in uninfected controls (light
gray) and after infection (black bars) with small colony variant SCV1 (A), SCV2
(B) or parent strain P1 (C) and treatment with loaded hydrogels: deferiprone
20 mM (Def, dark gray), gallium-protoporphyrin 500 µg/ml (GaPP, orange),
and Def-GaPP500 (red). Data represent the mean ± SEM of at least six
biological replicates. **p < 0.01; #p < 0.0001.
nutrient source leading to starvation. In addition, GaPP is
able to block eﬄux pumps essential for heme homeostasis
resulting in an intracellular accumulation of redox-active
molecules (Stojiljkovic et al., 2001; Reniere et al., 2007). The
subsequent antibacterial effects are based on starvation, limited
respiration and elevated production of reactive oxygen species
contributing to DNA and protein damage and ultimately cell
death.
FIGURE 8 | Log10 of CFU per C. elegans worm after 3 days infection (black
bars) with small colony variant SCV1 (A), SCV2 (B) or parent strain P1 (C) and
treatment with drug loaded hydrogels- Def: deferiprone 20 mM (gray), GaPP,
gallium-protoporphyrin 500 µg/ml (orange) and DG, Def-GaPP500 (red). Data
represent the mean ± SD of at least 6 biological replicates. *p < 0.05.
As shown in the present study, the combination of Def
and GaPP exhibited significant antibacterial and antibiofilm
activity against clinical isolates of S. aureus SCVs and a parent
strain. In the colony biofilm model, where compounds were
delivered in a surgical wound gel, a dose-dependent antibiofilm
effect of GaPP and Def-GaPP was observed (Figures 3, 5). A
colony biofilm comprises of a heterogeneous consortium of
sessile cells with a mixture of metabolic active bacteria on
the biofilm surface and metabolic retarded/inactive bacteria
on the inside. The metabolic activity arises due to different
oxygen levels (aerobic conditions on the biofilm surface, micro-
aerobic/anaerobic inside the biofilm) and different nutrient
availability according to the location bacteria occupy. While
Frontiers in Cellular and Infection Microbiology | www.frontiersin.org 7 June 2017 | Volume 7 | Article 280
Richter et al. Deferiprone and Gallium-Protoporphyrin Kill SCVs
sessile bacteria on the biofilm surface can relatively easily be
targeted, bacteria deeper in the biofilm are less exposed to
compounds and show reduced susceptibility (Merritt et al.,
2005). The blank gel and Def gel are thought to interfere
only with the biofilm surface by attaching to bacterial cell
wall proteins and depriving nutrients, respectively, resulting
in minor antibiofilm activity. Likewise, gels incorporating low
concentrations (100 µg/ml) of GaPP showed limited activity,
indicating an insufficient GaPP penetration into the colony
biofilm and/or a suboptimal GaPP concentration. A higher GaPP
concentration in gels (GaPP 500, Def-GaPP500) resulted in
higher antibiofilm activity. It was observed that the presence
of Def was crucial to facilitate a significant activity of GaPP
against SCV2 biofilms, which is likely based on a Def-induced
upregulation of heme acquisition systems elevating GaPP uptake
into bacteria for an improved antibiofilm effect. Another reason
for differences in susceptibility of the strains used in this study
can rely on auxotrophy (Garcia et al., 2013). SCVs can be
classified in two types of auxotrophs, namely hemin/menadione
auxotrophs and thymidine auxotrophs. This in return affects
the susceptibility toward antibiotics and other antibacterial
compounds (Garcia et al., 2013). SCV2 was observed to be
auxotrophic for thymidine, hence, less dependent on hemin/iron
which can explain the poor GaPP susceptibility. SCV1 was shown
to be hemin/menadione auxotrophic, thus, more susceptible to
the iron depriving and heme mimicking Def-GaPP treatment.
SCVs are electron-transport-defective strains with a reduced
transmembrane potential, which impedes the penetration and
activity of membrane active compounds and some antibiotic
classes, such as aminoglycosides and antifolate agents (von Eiff
et al., 1997a; McNamara and Proctor, 2000; Baumert et al., 2002).
Therefore, Gent was expected to show low activity against both
planktonic SCVs as confirmed in Table 1, and sessile SCVs as
seen in Figures 3, 5. Surprisingly, when Gent was combined with
Def-GaPP, the triple combination showed significant antibiofilm
activity (Figures 3, 5), indicating a potentiation of Gent by Def-
GaPP even against the Gent-tolerant SCV1 strain. This result
implies that by disrupting bacterial iron metabolism Def-GaPP
made the bacteria vulnerable and increased their susceptibility
to Gent for a synergistic antibiofilm effect as confirmed in
Figure 4. Similar results were observed for the treatment with
Cip. In line with the literature, planktonic SCVs showed higher
MIC values for Cip than the parent strain (Idelevich et al.,
2011) and biofilm-associated SCVs were also poorly susceptible
to Cip. In contrast, the combination of Def-GaPP-Cip showed
synergistic effects (Figure 4) resulting in significantly higher
antibiofilm activity, even when treatment with the individual
compounds was unsuccessful (Figure 3, SCV2). This confirms
that the combination of drugs with different modes of action can
be effective in treating bacteria with poor antibiotic susceptibility.
The higher efficacy of the triple combinations Def-GaPP-Cip
and Def-GaPP-Gent might rely on the synergy between reactive
oxygen species (resulting from the Def-GaPP treatment) and
antibiotics, as described elsewhere (Garcia L. G. et al., 2012;
Garcia et al., 2013).
The antibiofilm activity of Def-GaPP was furthermore
determined in an in vitro wound model where biofilms were
grown on an artificial dermis and exposed to loaded gels. In line
with results obtained in the colony biofilm model, Def-GaPP
gel showed substantial antibiofilm effects, though to a lower
extent. This may be the result of a nutrient-rich environment
with blood/heme as favorable iron source. Bacteria recognize
the tetrapyrrole ring of heme and GaPP, but can distinguish
between both compounds (Stojiljkovic et al., 1999; Moriwaki
et al., 2011). Therefore, GaPP gel showed only minor antibiofilm
activity, in contrast to the Def-GaPP combination. The Def-
induced chelation may have deprived bacteria of nutrients and
increased the uptake of GaPP as heme-mimicking agent for a
substantial antibiofilm effect of this “Trojan Horse” compound.
In an in vivo infection model in the nematode C.
elegans the antibacterial effect of Def-GaPP was assessed. It
was observed that the survival rate of infected nematodes
were strain-dependent (Figure 7). Literature described that
hemin/menadione auxotrophic strains were less virulent than
parent strains and thymidine auxotrophic strains (Sifri et al.,
2006). In line with this the order of virulence in the present
study was observed to be SCV1 (hemin/menadione auxotroph)
being the least and SCV2 (thymidine auxotroph) being the most
virulent strain (Figure 7). The auxotrophy type can influence
the strain’s susceptibility to antibacterial compounds. In the
colony biofilm model SCV1 was more susceptible to GaPP
and Def-GaPP than SCV2, which required the combination
of Def-GaPP for a substantial antibiofilm effect. Consistent
with these observations similar results were observed in vivo
in the C. elegans model. While infected nematodes died over
time due to bacterial colonization, biofilm formation and toxin
production (Sifri et al., 2005), the exposure to Def-GaPP
prolonged the lifespan of all infected nematodes (Figure 7) and
reduced the bacterial burden per worm (Figure 8). Treatment
with GaPP alone only increased the survival rate of SCV1 and P1
infected worms, but failed in SCV2 infected worms. Therefore,
combining GaPP with Def appeared to be crucial for an elevated
antibacterial activity against S. aureus SCVs of any auxotrophy
type.
CONCLUSION
The present study confirmed strong antibacterial and antibiofilm
properties of Def-GaPP against S. aureus SCVs in vitro and
in vivo. When applied in a surgical hydrogel, Def-GaPP has
potential to complement the gel’s wound healing properties
with antibacterial and antibiofilm effects and could serve as
an alternative treatment for biofilm and SCV-related infections.
Due to the risk of emerging antibiotic resistance, which is
in particular associated with prolonged antibiotic treatment,
the combination of drugs with different modes of action is
advantageous. The combination of Def-GaPP with antibiotics
may facilitate a multi-pronged approach to increase the
treatment efficacy against otherwise antibiotic tolerant/resistant
S. aureus SCVs. While the results of the current pilot study
are encouraging, the broader applicability of Def-GaPP for the
treatment of SCVs derived from other species is on the way to be
validated.
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